Zymeworks to Participate in Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences.

• Wells Fargo Securities’ 14th Annual Healthcare Conference is scheduled for September 4-5, 2019 in Boston, MA. Zymeworks is presenting on Wednesday, September 4, 2019 at 8:30 a.m. ET.
• Citi’s 14th Annual Biotech Conference is scheduled for September 4-5, 2019 in Boston, MA.
• Ladenburg Thalmann’s Healthcare Conference is scheduled for September 24, 2019 in New York, NY. Zymeworks is presenting on Tuesday, September 24, 2019 at 10:30 a.m. ET.

The Company will provide a corporate update and present upcoming catalysts. Interested parties can access a live webcast of the presentations via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host recorded replays available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005646/en/

Zymeworks Inc. 

Investor Inquiries: 
Ryan Dercho, Ph.D. 
(604) 678-1388 
[email protected] 

Tiffany Tolmie 
(604) 678-1388 
[email protected] 

Media Inquiries: 
Kavita Shah, Ph.D.
(604) 678-1388 
[email protected] 

Source: Zymeworks Inc.

You May Also Be Interested In

• Chinese Legal Expert Calls for Stronger Rule of Law to Advance China-Europe ESG Cooperation
• SK Telecom Pursues 15GW AI Data Center Buildout, Aiming to Become Asia's AI Infrastructure Hub
• Tiled Roof Restoration Services Expand Across Melbourne's West